Cabaletta Bio, Inc.
CABA
Last
$1.93
Day
-1.0%
1y
-31.6%
5y
-83.5%
52w
-53.9%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-0929d
EMA 21
2.24
EMA 50
2.55
EMA 200
2.81
20d high
-35.9%
5y high
-92.6%
5y range
5th
Positions held
Your positionsCABA isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-6
Hold
avoid
Signal
Sell
Target
$2.21
Stop
$1.73
Stop distance
10.4%
Target vs last
+14.5%
Fundamentals
| Market cap | $330.61M | Enterprise value | $131.23M | Trailing P/E | — | Forward P/E | -1.64 |
| PEG | — | Price / book | 1.55 | Beta | 3.48 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -93.2% | ROA | -48.2% | Debt / equity | 0.12 |
| Current ratio | 5.79 | Free cash flow | -$98.34M | Analyst recommendation | none | Mean target | $13.25 |
| 52w high | $4.23 | 52w low | $1.83 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$51.0M | -$43.5M | -$41.9M | -$44.9M | -$45.1M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$52.0M | -$44.3M | -$42.6M | -$46.6M | -$45.9M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$168M | -$116M | -$67.7M | -$53.0M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$172M | -$125M | -$74.7M | -$54.1M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-02 · Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
2026-09-01 · Cabaletta Bio to Participate in Upcoming Investor Conferences
2026-08-13 · Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Price (daily)
Full chart · RSI · MACD · patternsCABA · daily-22.0% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin